Sutro Biopharma (NASDAQ:STRO) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Sutro Biopharma (NASDAQ:STRO) from a sell rating to a hold rating in a research report report published on Saturday morning.

A number of other analysts have also weighed in on the stock. Wells Fargo & Company upgraded shares of Sutro Biopharma from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $8.00 to $27.00 in a research note on Tuesday, March 24th. Citizens Jmp upgraded shares of Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 target price for the company in a research report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Sutro Biopharma from $51.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday. Citigroup raised Sutro Biopharma to an “outperform” rating in a research report on Tuesday, January 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Monday, December 22nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sutro Biopharma has a consensus rating of “Moderate Buy” and a consensus target price of $37.29.

Sutro Biopharma Trading Down 1.9%

Shares of NASDAQ:STRO opened at $24.43 on Friday. Sutro Biopharma has a twelve month low of $5.23 and a twelve month high of $26.54. The company has a market cap of $207.90 million, a PE ratio of -0.94 and a beta of 1.47. The company’s 50 day moving average is $19.06 and its 200 day moving average is $12.97.

Hedge Funds Weigh In On Sutro Biopharma

Large investors have recently made changes to their positions in the company. Bridgeway Capital Management LLC boosted its holdings in Sutro Biopharma by 232.6% during the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after buying an additional 30,000 shares in the last quarter. Invesco Ltd. increased its holdings in Sutro Biopharma by 137.8% in the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after buying an additional 53,390 shares in the last quarter. Cerity Partners LLC increased its holdings in Sutro Biopharma by 169.9% in the second quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock valued at $75,000 after buying an additional 66,372 shares in the last quarter. Qube Research & Technologies Ltd acquired a new position in shares of Sutro Biopharma in the second quarter worth about $82,000. Finally, State of Tennessee Department of Treasury acquired a new position in shares of Sutro Biopharma in the fourth quarter worth about $86,000. 96.99% of the stock is currently owned by institutional investors and hedge funds.

Sutro Biopharma News Roundup

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target on STRO to $55, signaling strong upside from current levels; that lift to a much higher PT supports bullish investor sentiment. Deutsche Bank Raises Price Target to $55
• Positive Sentiment: Wells Fargo upgraded Sutro to “Overweight,” an endorsement that can attract institutional buying. Wells Fargo Upgrades Sutro Biopharma to Overweight
• Positive Sentiment: Truist moved the stock to “strong-buy” (reported via Zacks), another supportive vote of confidence from the sell side. Truist Upgrades to Strong-Buy (Zacks)
• Neutral Sentiment: HC Wainwright published commentary on Sutro’s FY2030 outlook — the note offers long‑range modeling context but is not a straightforward buy/sell trigger by itself. HC Wainwright Comments on Sutro FY2030 Earnings
• Negative Sentiment: HC Wainwright sharply cut near‑term and multi‑year EPS forecasts (Q1–Q4 FY2026 and FY2026–FY2029), moving projected losses much deeper while keeping a Buy rating and a $28 target. Those sizable downward revisions increase short‑term downside risk and help explain selling pressure despite upgrades. HC Wainwright Lowers Multiple EPS Estimates (MarketBeat)

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.